anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a glossy ganoderma-lentinus edodes stem solid state fermentation compound as well as a preparation method and application thereof. The glossy ganoderma-lentinus edodes stem solid state fermentation compound is characterized in that the glossy ganoderma is fermented and cultured by using lentinus edodes stems serving as culture mediums to obtain the compound of the culture medium and the culture, and the compound comprises a mixture of the lentinus edodes stems and the glossy ganoderma which are discomposed. The preparation method of the glossy ganoderma-lentinus edodes stem solid state fermentation compound comprises the steps of: A-1. rejuvenation and screening of strains; A-2. expanding propagation and cultivation; B-1. primary selection of the lentinus edodes stems; B-2. cleaning of the lentinus edodes stems; B-3. drying of the lentinus edodes stems; B-4. crushing of the lentinus edodes stems; B-5. batching of the soldi state fermentation medium; B-6. charging and sterilization; B-8. fermented cultivation; and C. aftertreatment. The glossy ganoderma-lentinus edodes stem solid state fermentation compound has good anti-aging and antioxidant effects; and the preparation method is a high-efficient deep-processing development technology of lentinus edodes stem wastes.
A compound represented by the formula (I): [wherein A1 represents hydrogen, etc.; j and k each is 0 or 1; ~ (P)j = represents a double bond, etc.; ~ (Q)k = represents a double bond, etc.; and one of W1 and W2 represents E-O-W, etc.  and the other represents hydrogen, etc., provided that E represents a divalent group formed by removing two hydrogen atoms from a benzene ring, etc. and W  represents a group represented by the formula (II-1)] or a pharmaceutically acceptable salt of the compound. The compound and salt have antagonistic activity against a histamine H3 receptor or inverse agonistic activity against a histamine H3 receptor and are useful in the prevention or treatment of metabolic diseases, circulatory diseases, or nervous diseases.
In Cohort 2 subjects will receive either GSK2248761 in the range of 10 mg - 20 mg or 40 mg - 90 mg or placebo once a day for 7 days. On Day 8 subjects will receive either Kaletra or HAART for 28 days. The doctor will choose the most appropriate medications for HAART. The dose for Cohort 2 will be determined following evaluation of results from Cohort 1. Cohort 2 may not be done.
Self-rated health (SRH), an indicator of overall health status, has been associated with morbidity and mortality. Yet links between SRH and nutrition are lacking, especially in conjunction with other characteristics affecting SRH. Therefore, the study objective was to identify significant sociodemographic/socioeconomic, chronic disease, dietary habits, and food environment explanatory variables for perceptions of self-rated health (SRH). Data were collected in 2021 and consisted of households at risk of or experiencing food insecurity. Multivariable logistic regression was used to identify significant explanatory variables for SRH. Of the 54% of participants with low SRH, 43% had nutrition insecurity and 66% had one or more chronic disease. For participants with high SRH, 25% had nutrition insecurity and 32% had one or more chronic disease. Household income, fruit and vegetable intake, and scratch-cooked meals consumption were protective against low SRH (5%-16% decrease in odds). Participants with low SRH were 1.8 and 4.3 times as likely to have nutrition insecurity and one or more chronic disease, respectively than participants with high SRH. Perceptions of one's health are positively associated with healthful dietary habits and negatively associated with nutrition insecurity and presence of chronic disease.
Patients with vascular anomalies (VA) have a spectrum of diseases that can be broadly classified into vascular tumors and malformations. Complicated vascular anomalies can cause disfigurement, chronic pain, and organ dysfunction with significant morbidity and mortality. Despite the severity of potential complications, we lack uniform guidelines for the treatment and response to treatment of children and young adults with these diseases. There are pre-clinical and clinical data supporting the essential regulatory function of the PI3K/Akt/mTOR pathway in vascular growth and organization, and suggest a therapeutic target for patients with complicated vascular anomalies. The overall goal of this trial is to objectively determine the effectiveness and safety of the mTOR inhibitor Rapamycin\* in the treatment of children and young adults diagnosed with complicated vascular anomalies. We propose a Phase 2 trial with the diagnostic, therapeutic and response criteria experimentally determined in this study used as a framework for future Phase 3 clinical trials.
OBJECTIVE: To investigate how people with shoulder problems and their physiotherapists perceive the recovery of shoulder problems.
METHOD: We performed a qualitative study using semi-structured interviews with patients and their physiotherapists. Nine pairs of patients and physiotherapists (n = 18) were recruited. The transcribed interviews were analyzed in a consecutive multistep iterative process using a conventional content analysis.
RESULTS: Analysis of the interviews resulted in three major themes: 'What do I expect from my recovery?', 'Am I recovering?' and 'When do I consider myself recovered?' The patients and physiotherapists talked similarly about the importance of and interdependency between these themes. Central to these three themes are the analysis of the cause of shoulder problems and the experience of uncertainty. Our analyses suggest that there are conceptual differences in how patients and physiotherapists formulate their expectations about recovery, observe the recovering process, and conceptualize when someone may be considered recovered. Different interpretations by the patients of the information provided by the physical therapists appeared to fuel these differences.
CONCLUSION: Our results show that the concept of recovery is defined by patients and physiotherapists in three distinct themes. Within these themes the patients and physiotherapists differ substantially in their conceptualization of the recovery.
IMPACT STATEMENT: This insight in the concept of recovery can help patients and physiotherapists better understand each other, enhance the alignment of ideas about the care process, and support making decisions together. Physiotherapists should be aware that patients might interpret their words, explanations, and expectations substantially different.
Post-Injection Delirium/Sedation Syndrome — Adverse events with signs and symptoms consistent with olanzapine overdose, in particular, sedation (including coma) and/or delirium, have been reported following injections of ZYPREXA RELPREVV. ZYPREXA RELPREVV must be administered in a registered healthcare facility with ready access to emergency response services. After each injection, patients must be observed at the healthcare facility by a healthcare professional for at least 3 hours. Because of this risk, ZYPREXA RELPREVV is available only through a restricted distribution program called ZYPREXA RELPREVV Patient Care Program and requires prescriber, healthcare facility, patient, and pharmacy enrollment [see Dosage and Administration (2.1), Warnings and Precautions (5.1, 5.2), Overdosage (10.2), and Patient Counseling Information (17)]. 

Increased Mortality in Elderly Patients with Dementia-Related Psychosis — Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. ZYPREXA RELPREVV is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.3), Use in Specific Populations (8.5) and Patient Counseling Information (17)].
Trail treatment with AsthmaTuner up to 3 months. Objective asthma criteria: Positive reversibility test, FEV1 \>12% and 200 ml or positive periodic variability PEF/FEV1 \>20%. Treatment recommendation is prescribed individually by treating physician.
This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment will continue for a total of 3 treatment cycles.
BACKGROUND: Shift work can disrupt sleep quality and gut health. Nurses and midwives constitute approximately half of the global healthcare shift-working workforce. Our previous study revealed that most midwives were experiencing suboptimal health conditions, characterized by poor sleep quality and a high prevalence of gastrointestinal diseases. The gut-brain axis theory highlights the potential interplay between sleep quality and gut health. However, limited research focuses on this relationship among midwives.
METHODS: A cross-sectional survey included 2041 midwives from 87 Chinese hospitals between March and October 2023. Participants completed standardized questionnaires assessing sleep quality, gut health, depression, anxiety, and work stress. Binary logistic regression analyzed factors associated with poor sleep, and multiple linear regression examined the influence of sleep quality on gut health.
RESULTS: Over 60% of midwives reported poor sleep, with many experiencing gastrointestinal disorders. We observed a bidirectional relationship between sleep quality and gut health among midwives. After multivariable adjustments, midwives with higher gut health scores were more likely to experience poor sleep quality (odds ratio = 1.042, 95% confidence interval = 1.03-1.054). Conversely, midwives with higher sleep quality scores were also more likely to have poor gut health (β = 0.222, 95% confidence interval = 0.529-0.797). These associations remained robust across sensitivity analyses. Furthermore, depression, anxiety, and work stress significantly affected both sleep quality and gut health among midwives.
CONCLUSION: This study enhances our understanding of the intricate relationship between sleep quality and gut health among midwives. Poor gut health was associated with a higher risk of poor sleep, and vice versa. To improve the overall wellbeing of midwives, the findings emphasize the importance of addressing poor sleep quality and promoting gut health through maintaining a healthy diet, lifestyle, and good mental health. Further studies are needed to confirm our findings and clarify the underlying mechanisms.
OBJECTIVE: The American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine endorse checklist use to improve obstetric care. However, there is limited research into development, implementation, and sustained use of perinatal emergency checklists to inform individual institutions. This study aimed to investigate the development and implementation of perinatal emergency checklists in diverse hospital settings in the United States.
STUDY DESIGN: A qualitative study was conducted individually with clinicians from three health care systems. The participants developed and implemented institution-tailored perinatal emergency checklists. Interview transcriptions were coded using the Consolidated Framework for Implementation Research.
RESULTS: The study sites included two health care systems and one individual hospital. Delivery volumes ranged from 3,500 to 48,000 deliveries a year. Interviews were conducted with all 10 participants approached. Checklists for 19 perinatal emergencies were developed at the three health care systems. Ten of the checklist topics were the same at all three institutions. Participants described the checklists as improving patient care during crises. The tools were viewed as opportunities to promote a shared mental model across clinical roles, to reduce redundancy and coordinate obstetric crisis management. Checklist were developed in small groups. Implementation was facilitated by those who developed the checklists. Participants agreed that simulation was essential for checklist refinement and effective use by response teams. Barriers to implementation included limited clinician availability. There was also an opportunity to strengthen integration of checklists workflow early in perinatal emergencies. Participants articulated that culture change took time, active practice, persistence, reinforcement, and process measurement.
CONCLUSION: This study outlines processes to develop, implement, and sustain perinatal emergency checklists at three institutions. Participants agreed that multiple, parallel implementation tactics created the culture shift for integration. The overview and specific Consolidated Framework for Implementation Research components may be used to inform adaptation and sustainability for others considering implementing perinatal emergency checklists.
KEY POINTS: · Perinatal emergency checklists reduce redundancy and coordinate obstetric crisis management.. · Perinatal emergency simulation is essential for checklist refinement and effective team use.. · Integrations of perinatal emergency checklists requires culture change and process measurement..
Patients with lower than expected cyclosporine blood trough concentrations in relation to the oral dose of Sandimmune® (Cyclosporine Capsules USP) may have poor or inconsistent absorption of cyclosporine from Sandimmune® (Cyclosporine Capsules USP). After conversion to Cyclosporine Capsules USP MODIFIED, patients tend to have higher cyclosporine concentrations. Due to the increase in bioavailability of cyclosporine following conversion to Cyclosporine Capsules USP MODIFIED, the cyclosporine blood trough concentration may exceed the target range. Particular caution should be exercised when converting patients to Cyclosporine Capsules USP MODIFIED at doses greater than 10 mg/kg/day. The dose of Cyclosporine Capsules USP MODIFIED should be titrated individually based on cyclosporine trough concentrations, tolerability, and clinical response. In this population the cyclosporine blood trough concentration should be measured more frequently, at least twice a week (daily, if initial dose exceeds 10 mg/kg/day) until the concentration stabilizes within the desired range.
The invention provides an intelligent closestool with a health detection function, which comprises the following components: the toilet comprises a toilet body, an upper cover, a seat ring, a water tank component and a health detection system. Wherein the health detection system comprises: the system comprises a control center, a physical sign information input storage module, an identity recognition module, an excrement detection module and a communication module, wherein the physical sign information input storage module, the identity recognition module, the excrement detection module and the communication module are electrically connected with the control center. The physical sign information input storage module is used for inputting and storing the weight information of a plurality of users. The excrement detection module is used for detecting an excrement sample of a current user and sending detection information to the control center. The control center is used for analyzing the detection information to obtain the health information of the current user, and sending the health information of the current user to the communication equipment of the current user through the communication module. This intelligent closestool with health detection function can monitor user's health status to intelligent closestool's function has been strengthened, user experience has been improved.
PURPOSE:To obtain a power cosmetic having both excellent moist touch and utility such as ready handleability, containing a nonvolatile fluorine-based liquid oil solution and organic low-molecular pigment. CONSTITUTION:A cosmetic containing 0.1-50wt.% nonvolatile fluorine-based liquid oil solution (e.g. perfluoropolyether) and 1.0-99.0wt.% organic low- molecular pigment (e.g. zinc salt of monoalkylphosphoric acid). The cosmetic is properly blended with powder (e.g. titanium oxide), oil solution for cosmetic, surfactant, antioxidant, perfume, dyestuff, alcohol, humectant, ultraviolet light absorber, etc., useful for other ordinary powder cosmetic and prepared by conventional procedure to give the objective substance. The substance can be made into a cosmetic such as face powder, body powder, powder foundation, cheek rouge and eye shadow. The cosmetic will not cause caking in a solid state and will not produce aggregate in the case of loose type.
X-Ray contrast agents in aerosol form for bronchography contain finely dispersed Ta metal pref. of particle size 2-50 mu. They are used in the diagnosis of bronchial carcinoma; the larger particles show up the upper airways and the finer ones the bronchioles. Prepn. is by suspension of fine Ta powder in a propellent e.g. CCl2F2, CCl3F, C2Cl2F4, C2Cl3F3 or mixts. of these. The suspension may alxo contain surfactants or suspension stabilisers. Application is by inhalation from containers fitted with dose regulators giving 0.005-0.2 g Ta at a time.
The invention discloses for the first time pluripotent cells, including hypoimmune pluripotent ABO blood type O Rhesus Factor negative (HIPO−) cells, that evade rejection by the host allogeneic immune system and avoid blood antigen type rejection. The HIPO− cells comprise reduced HLA-I and HLA-II expression, increased CD47 expression, and a universal blood group O Rh− (“O−”) blood type. The universal blood type is achieved by eliminating ABO blood group A and B antigents as well as eliminating Rh factor expression, or by starting with an O− parent cell line. These new, novel HIPO− cells evade host immune rejection because they have an impaired antigen presentation capacity, protection from innate immune clearance, and lack blood group rejection. The cells of the invention also include O− pluripotent stem cells (iPSCO−) and O− embryonic stem cells (ESCO−). The invention further provides universally acceptable “off”-the-shelf pluripotent cells and derivatives thereof for generating or regenerating specific tissues and organs.
Objective:To analyze the difference in 5-year survival between maxillary sinus adenoidal cystic carcinoma(maxillary sinus adenoid cystic carcinoma, MSACC) and squamous cell carcinoma(maxillary sinus squamous cell carcinoma, MSSCC) using the National Cancer Institute's Surveillance, Epidemiology, and End. Results:database(SEER) and to explore the factors associated with the prognosis of the two tumors. Methods:The data of 161 patients with MSACC and 929 patients with MSSCC were collected from SEER database, and the 5-year overall survival rate(OS) and tumor specific survival rate(CSS) were compared between the two groups before and after propensity score matching. The forest map of multivariate Cox proportional hazard regression model was established to analyze the prognostic factors affecting the survival rate of patients with MSACC and MSSCC. Results:There were statistical differences in 5-year OS and CSS between MSACC and MSSCC before and after propensity score matching(P<0.001). Multivariate regression analysis showed that age, side of the disease, lymph node metastasis, operation and radiotherapy were the influencing factors of OS in MSACC, while age and operation were the influencing factors of CSS. Age, race, T grade, lymph node metastasis, systemic metastasis, surgery, radiotherapy and chemotherapy are the influencing factors of OS of MSSCC. Age, T grade, lymph node metastasis, systemic metastasis, surgery, radiotherapy and chemotherapy are the influencing factors of CSS. Conclusion:The 5-year survival rate of MSACC is higher than that of MSSCC. Surgery plays a positive role in the prognosis of the two kinds of tumors. The analysis results can provide some reference for their survival expectations and treatment choices.
Study Design We will conduct a 2-arm randomized controlled trial to evaluate the impact of a telehealth delivered survivorship transition care process. Ovarian cancer survivors (120) will be randomly allocated to receive survivorship care either using the POSTCare Process or standard of care. Study design and reporting will be in accordance with the Consolidated Standards of Reporting Trials (CONSORT) checklist. We will use quantitative and qualitative methodologies in a concurrent triangulation mixed methods design utilizing qualitative data to augment our interpretation of quantitative data. Outcomes will be collected at baseline, 12 weeks and 24 weeks, with the primary outcome being quality of life assessment at 12 weeks.

Sample Size We will enroll 120 women completing primary treatment for Stage 2-4 ovarian cancer from 3 urban gynecologic oncology clinics located in the Southern United States. Participants will have received some combination of surgery, chemotherapy, radiation therapy, and biologics. Continued maintenance therapy is not an exclusion factor. Aim 1 proposes to implement a randomized controlled trial (RCT) devised to compare QOL measures among ovarian cancer patient randomized to receive usual care versus the POSTCare survivorship care transition program. The Functional Assessment of Cancer Therapy-Ovarian (FACT-O) QOL survey will be collected at baseline as well as 12 and 24 weeks after the initial course of adjuvant chemotherapy. The primary endpoint will be the 12-week survey. We expect to observe a mean 12-week FACT-O score of 116 with standard deviation of 20 for women receiving usual care. The sample size of N=120 patients provides at least 80% power to detect a 7% increase in the mean FACT-O score for women randomized to the POSTCare survivorship care intervention. This is sufficient to ascertain a minimally important difference of 8 points.

Recruitment and Setting We will recruit participants from Gynecologic Oncology practices at 3 clinic settings in Texas: One safety net practice located in Dallas, one safety net practice located in Houston, and one faculty group practice located in Houston. Cumulatively the sites serve approximately 120 eligible patients per year and ensure a diverse population can be recruited during the 24-month recruitment period. 120 women will be recruited. Sixty participants will be randomly assigned to the intervention group and receive care using the POSTCare Process and 60 will be randomly assigned to the control group. It is anticipated that our study sample will reflect the ethnic and racial diversity of our clinical settings.